Imatinib and dasatinib, which disrupt BCR- and ABL-mediated oncogenic signalling in CML, depleted the levels of MDSCs and their biomarkers IL-10, ARG1, and myeloperoxidase [62]. Here, ARG1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.